Gallium68PSMAQualityChecker

Gallium-68 PSMA Quality Checker — ⁶⁸Ga-PSMA-11 for prostate cancer PET imaging (Ph. Eur. 2.14.5, USP <823>, EMA)

ℹ️  The utility checks specific activity, radiochemical purity, germanium-68 impurity, free ligand, pH, endotoxins, sterility, heavy metals, aluminium, residual solvents (ethanol, acetonitrile).
ℹ️  Does not use machine learning — rule-based logic only.
⚠️  CRITICAL: Specific activity ≥100 GBq/μmol — critical for low PSMA expression tumors! Free ligand ≤3% — competes for PSMA receptors! Germanium-68 impurity ≤0.001% — 271-day half-life!

Usage:
  Gallium68PSMAQualityChecker.exe                            → demo mode (console output)
  Gallium68PSMAQualityChecker.exe input.csv output.json      → evaluate your data

Input format:
BatchNumber,SpecificActivityGBqPerUmol,RadiochemicalPurityPercent,Germanium68ImpurityPercent,FreeLigandPercent,pH,EndotoxinsEU,SterilityTest,HeavyMetalsPPM,AluminiumPPM,ResidualEthanolPPM,ResidualAcetonitrilePPM

Example (sterility: 0=sterile, 1=contaminated):
Ga68-PSMA-2026-001,120.0,97.5,0.0005,2.0,6.2,120.0,0,5,5.0,2000,300

— WHY IS THIS NEEDED?
⁶⁸Ga-PSMA-11 — modern PET radiopharmaceutical for prostate cancer imaging:
• Binding to prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells
• High sensitivity and specificity for detecting primary tumors, metastases, and recurrences
• Used for staging, therapy planning, and treatment response monitoring
⚠️ CRITICAL:
• Specific activity ≥100 GBq/μmol — HIGHER than ⁶⁸Ga-DOTATATE (≥50 GBq/μmol)! Critical for effective binding to low-expressing PSMA receptors. Low specific activity = insufficient tumor uptake = false-negative results.
• Radiochemical purity ≥95.0% — ensures radiation delivery specifically to tumor cells
• Germanium-68 impurity ≤0.001% — CRITICAL! Germanium-68 has 271-DAY half-life! Even 0.0011% creates chronic radiation burden to patient without diagnostic benefit. Generator breakthrough control is mandatory!
• Free ligand ≤3.0% — UNBOUND LIGAND COMPETES FOR PSMA RECEPTORS! Reduces tumor uptake by 20-40% per clinical studies. Stricter than DOTATATE (≤5%).
• Aluminium <10 ppm — concentrations ≥10 ppm cause bone uptake artifacts on PET, masking true metastases
• pH 4.5–7.5 — critical for blood compatibility during intravenous administration
• Endotoxins ≤175 EU/vial — critical for intravenous administration! Exceeding causes pyrogenic reactions
• Sterility — MANDATORY for all parenteral forms! Contamination = unfit for use
⚠️ Special attention: Specific activity of ⁶⁸Ga-PSMA-11 (≥100 GBq/μmol) is SIGNIFICANTLY HIGHER than ⁶⁸Ga-DOTATATE (≥50 GBq/μmol). This is due to low PSMA expression on some tumor cells. Even minor reduction in specific activity (to 95 GBq/μmol) can lead to insufficient tumor uptake. Free ligand is especially critical — competition for receptors directly reduces diagnostic sensitivity. Germanium-68 impurity is the most critical parameter for all generator-based agents!
Critical parameters:
• Specific activity: ≥100 GBq/μmol (HIGHER than ⁶⁸Ga-DOTATATE!)
• Radiochemical purity: ≥95.0%
• Germanium-68 impurity: ≤0.001% (CRITICAL: 271-DAY HALF-LIFE!)
• Free ligand: ≤3.0% (UNBOUND LIGAND REDUCES TUMOR UPTAKE!)
• pH: 4.5–7.5 (blood compatibility)
• Endotoxins: ≤175 EU/vial (LAL test)
• Sterility: no microbial growth
• Heavy metals: ≤10 ppm
• Aluminium: <10 ppm (IMAGE ARTIFACTS!)
• Residual ethanol: ≤5000 ppm
• Residual acetonitrile: ≤410 ppm (ICH Q3C Class 2 — NEUROTOXIC!)
⚠️ Note: Utility is designed for quality control of FINISHED INJECTABLE SOLUTION. All parameters comply with parenteral form requirements for prostate cancer PET imaging. Due to short gallium-68 half-life (68 minutes), quality control must be completed within 15–25 minutes after labeling. Utility speeds up result processing 5-10x. Specific activity, free ligand, and germanium-68 impurity are key parameters for clinical efficacy.